Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CTX-1 + Nutlin-3a |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTX-1 | CTX1 | MDM4 inhibitor 8 | CTX-1 binds to and inhibits Mdm4 (MdmX), which disrupts the interaction between Tp53 and Mdm4, leading to stabilization of Tp53 and potentially leading to increased tumor cell death (PMID: 26883273). | |
Nutlin-3a | Nutlin|Nutlin-3 | MDM2 Inhibitor 23 | Nutlin-3a is an MDM2 inhibitor that activates p53, potentially resulting in induction of apoptosis and senescence in tumor cells (PMID: 18451145, PMID: 32653500). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | acute myeloid leukemia | sensitive | CTX-1 + Nutlin-3a | Preclinical | Actionable | In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273). | 26883273 |
TP53 wild-type | Advanced Solid Tumor | sensitive | CTX-1 + Nutlin-3a | Preclinical | Actionable | In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273). | 26883273 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|